Hypersensitivity reactions to tocilizumab: Role of skin tests in diagnosis

Rheumatology (United Kingdom)

Volumn 53, Issue 8, 2014, Pages 1527-1529

  Rocchi, Valeria ^a   Puxeddu, Ilaria ^a   Cataldo, Giuseppe ^a   Del Corso, Isabella ^a   Tavoni, Antonio ^a   Bazzichi, Laura ^a   Bombardieri, Stefano ^a   Migliorini, Paola ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; INFLIXIMAB; TOCILIZUMAB;

CELL ACTIVATION; DRUG HYPERSENSITIVITY; DRUG SENSITIZATION; HUMAN; IN VIVO STUDY; LETTER; MAST CELL DEGRANULATION; PRIORITY JOURNAL; SKIN ANAPHYLAXIS; SKIN TEST; URTICARIA;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; SKIN; SKIN TESTS;

EID: 84904890986     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu181     Document Type: Letter

References (10)

1. Al-Shakarchi I, Gullick NJ, Scott DL. Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. Patient Prefer Adherence 2013;7:653-66.
2. Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
3. Nakamura M, Tokura Y. Tocilizumab-induced erythroderma. Eur J Dermatol 2009;19:273-4.
4. Yoshiki R, Nakamura M, Tokura Y. Drug eruption induced by IL-6 receptor inhibitor tocilizumab. J Eur Acad Dermatol Venereol 2010;24:495-6.
5. Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 2014;73:95-100.
6. Simons FE, Ardusso LR, Bilò MB et al. 2012 Update: World Allergy Organization guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol 2012;12:393-9.
7. Brockow K, Garvey LH, Aberer W et al. The ENDA/EAACI Drug Allergy Interest Group. Skin test concentrations for systemically administered drugs-an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013;68:702-12.
8. Matucci A, Pratesi S, Petroni G et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy 2013;43:659-64.
9. Stubenrauch K, Wessels U, Birnboeck H et al. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010;32:1597-609.
10. Ebo DG, Leysen J, Mayorga C et al. The in vitro diagnosis of drug allergy: status and perspectives. Allergy 2011;66:1275-86.